ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

ClinicalTrials.gov ID: NCT03567291

Public ClinicalTrials.gov record NCT03567291. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

Study identification

NCT ID
NCT03567291
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Enrollment
228 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • TEV-50717 Drug

Drug

Eligibility (public fields only)

Age range
6 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 24, 2018
Primary completion
May 14, 2020
Completion
May 14, 2020
Last update posted
Nov 8, 2021

2018 – 2020

United States locations

U.S. sites
33
U.S. states
18
U.S. cities
30
Facility City State ZIP Site status
Teva Investigational Site 046-0104 Dothan Alabama 36303
Teva Investigational Site 046-0107 Rogers Arkansas 72758
Teva Investigational Site 046-0126 Anaheim California 92805
Teva Investigational Site 046-0101 Sacramento California 95815
Teva Investigational Site 046-0111 San Diego California 92108
Teva Investigational Site 060-0160 Gainesville Florida 32608
Teva Investigational Site 060-0166 Gulf Breeze Florida 32561-4458
Teva Investigational Site 060-0161 Miami Florida 33136-2107
Teva Investigational Site 046-0115 Orlando Florida 32803
Teva Investigational Site 060-0153 Orlando Florida 32819
Teva Investigational Site 046-0114 St. Petersburg Florida 33701
Teva Investigational Site 046-0116 Atlanta Georgia 30331
Teva Investigational Site 060-0155 Chicago Illinois 60612
Teva Investigational Site 060-0164 Chicago Illinois 60634
Teva Investigational Site 046-0133 Naperville Illinois 60563
Teva Investigational Site 046-0128 Boston Massachusetts 02114
Teva Investigational Site 060-0170 Bridgeton Missouri 63044
Teva Investigational Site 046-0110 Saint Charles Missouri 63304
Teva Investigational Site 046-0134 Lincoln Nebraska 68526-9467
Teva Investigational Site 046-0109 Voorhees Township New Jersey 08043
Teva Investigational Site 046-0124 New York New York 10029
Teva Investigational Site 060-0154 New York New York 10036
Teva Investigational Site 046-0102 Rochester New York 14618
Teva Investigational Site 046-0106 Oklahoma City Oklahoma 73116
Teva Investigational Site 060-0169 Charleston South Carolina 29414-5834
Teva Investigational Site 060-0156 Nashville Tennessee 37232-2551
Teva Investigational Site 046-0113 Dallas Texas 75243
Teva Investigational Site 060-0163 Fort Worth Texas 76104
Teva Investigational Site 046-0108 Houston Texas 77030
Teva Investigational Site 046-0120 San Antonio Texas 78249
Teva Investigational Site 046-0105 Orem Utah 84058
Teva Investigational Site 046-0118 Petersburg Virginia 23805
Teva Investigational Site 060-0162 Everett Washington 98201-4077

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03567291, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2021 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03567291 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →